Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
- Author
- MISHANI, Eyal1 ; ABOURBEH, Galith1 ; EIBLMAIER, Martin2 ; ANDERSON, Carolyn J2 3
[1] Department of Nuclear Medicine, Cyclotron Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel
[2] Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
[3] Department of Chemistry, Washington University, St. Louis, MO, United States - Issue title
- Imaging of Tumor Characteristics for Tailored Therapy
- Author (monograph)
- DE VRIES, Erik (Editor)1
[1] Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Netherlands - Source
Current pharmaceutical design (Print). 2008, Vol 14, Num 28, pp 2983-2998, 16 p ; ref : 119 ref
- ISSN
- 1381-6128
- Scientific domain
- Pharmacology drugs
- Publisher
- Bentham, Sharjah
- Publication country
- United Arab Emirates
- Document type
- Article
- Language
- English
- Author keyword
- EGFR PET cancer cetuximab gefitinib imaging tyrosine kinase
- Keyword (fr)
- Anticancéreux Article synthèse Cétuximab Formation image Géfitinib Imagerie médicale Immunomodulateur Médecine nucléaire Protein-tyrosine kinase Récepteur facteur croissance épiderme Surexpression génique Technologie pharmaceutique Tomographie par émission de positons Tomoscintigraphie Tumeur maligne Anti-EGFR Anticorps monoclonal Cancer Dérivé de la quinazoline Enzyme Exploration radioisotopique Inhibiteur de la tyrosine kinase Inhibiteur enzyme Transferases
- Keyword (en)
- Antineoplastic agent Review Cetuximab Imaging Gefitinib Medical imagery Immunomodulator Nuclear medicine Protein-tyrosine kinase Epidermal growth factor receptor Gene overexpression Pharmaceutical technology Positron emission tomography Emission tomography Malignant tumor Monoclonal antibody Cancer Quinazoline derivatives Enzyme Radionuclide study Tyrosine kinase inhibitor Enzyme inhibitor Transferases
- Keyword (es)
- Anticanceroso Artículo síntesis Cetuximab Formación imagen Gefitinib Imaginería médica Inmunomodulador Medicina nuclear Protein-tyrosine kinase Receptor del factor de crecimiento epidérmico Sobreexpresión genética Tecnología farmacéutica Tomografía emisión positrones Tomocentelleografía Tumor maligno Anticuerpo monoclonal Cáncer Enzima Exploración radioisotópica Inhibidor tyrosine kinase Inhibidor enzima Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04H Treatment. General aspects
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B24 Investigative techniques, diagnostic techniques (general aspects) / 002B24B Radionuclide investigations / 002B24B11 Miscellaneous. Technology
- Discipline
- Pharmacological treatments Scanning and diagnostic techniques Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 21034106
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2174/138161208786404326 
https://dx.doi.org/10.2174/138161208786404326
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161208786404326\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"2983\";s:8:\"\u0000*\u0000epage\";s:4:\"2998\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MISHANI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Eyal\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"ABOURBEH, Galith\";i:1;s:17:\"EIBLMAIER, Martin\";i:2;s:19:\"ANDERSON, Carolyn J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"Imaging of Tumor Characteristics for Tailored Therapy\";s:8:\"\u0000*\u0000title\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161208786404326\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"2983\";s:8:\"\u0000*\u0000epage\";s:4:\"2998\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MISHANI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Eyal\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"ABOURBEH, Galith\";i:1;s:17:\"EIBLMAIER, Martin\";i:2;s:19:\"ANDERSON, Carolyn J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"Imaging of Tumor Characteristics for Tailored Therapy\";s:8:\"\u0000*\u0000title\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161208786404326\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161208786404326\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"2983\";s:8:\"\u0000*\u0000epage\";s:4:\"2998\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MISHANI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Eyal\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"ABOURBEH, Galith\";i:1;s:17:\"EIBLMAIER, Martin\";i:2;s:19:\"ANDERSON, Carolyn J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"Imaging of Tumor Characteristics for Tailored Therapy\";s:8:\"\u0000*\u0000title\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161208786404326\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"2983\";s:8:\"\u0000*\u0000epage\";s:4:\"2998\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MISHANI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Eyal\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"ABOURBEH, Galith\";i:1;s:17:\"EIBLMAIER, Martin\";i:2;s:19:\"ANDERSON, Carolyn J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"Imaging of Tumor Characteristics for Tailored Therapy\";s:8:\"\u0000*\u0000title\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161208786404326\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:2:\"28\";s:8:\"\u0000*\u0000spage\";s:4:\"2983\";s:8:\"\u0000*\u0000epage\";s:4:\"2998\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MISHANI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Eyal\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"ABOURBEH, Galith\";i:1;s:17:\"EIBLMAIER, Martin\";i:2;s:19:\"ANDERSON, Carolyn J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:53:\"Imaging of Tumor Characteristics for Tailored Therapy\";s:8:\"\u0000*\u0000title\";s:96:\"Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
